You are here:HomeLive TVVideosNewsExpect $125-150 Mn From Oral Contraceptives Business: Lupin

Expect $125-150 mn from oral contraceptives business: Lupin


Lupin has received approval to launch the generic version of oral contraceptive Yasmin in the US. Ramesh Swaminathan, president of finance and planning, Lupin, explains this is a crucial product for the pharma company and could help them garner $125-150 million dollars over time. He adds that Lupin has a strong pipeline of launches for the year ahead as well.

Social Sharing


  • BSE
  • NSE
Company Price (Rs.) CHG %
APOLLOTYRE 173.00 7.49%
CROMPGREAV 188.85 6.57%
ARVIND 192.00 6.19%
IRB 117.10 6.07%
More from Top Gainers »
Don't Miss


Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2014. All rights reserved.